Because CASP3/DR combined with XIAP:CASP7 accumulation correlates with the aggressive evolution of clinical malignancies and a poor prognosis in cancer patients, targeting XIAP:CASP7 represents an effective treatment against these malignant cancers [15]. This evidence concerns the gene CASP7 and cancer.